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A B S T R A C T
Purpose
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV) –related malignancy express-
ing EBV antigens that are possible targets of cell therapy, including latent membrane protein
2 (LMP2). We conducted a clinical trial of EBV-targeted cell therapy with autologous virus-
specific cytotoxic T lymphocytes (CTLs) for NPC refractory to conventional treatments.
Patients and Methods
Ten patients with EBV-related stage IV NPC in progression after conventional radiotherapy
and chemotherapy received intravenously autologous EBV-specific CTLs reactivated and ex-
panded ex vivo from peripheral blood lymphocytes through stimulation with EBV-transformed
autologous B-lymphoblastoid cell lines (LCL). Toxicity, specific cellular immune responses,
and clinical tumor responses were evaluated.
Results
EBV-specific CTLs could be generated in all patients and were predominantly CD3/CD8
T lymphocytes displaying specific killing of autologous EBV-LCL, autologous NPC cells as well
as autologous targets bearing the EBV antigen LMP2. Patients received two to 23 infusions
of EBV-specific CTLs that were well tolerated with the exception of grade 1 to 2 inflammatory
reactions at the tumor site in two cases. Control of disease progressionwas obtained in six of
10 patients (two with partial response and four with stable disease). Analysis of interferon-–
producing cells demonstrated an increased frequency of EBV-specific immunity, with appear-
ance of LMP2-specific responses in four patients, of whom three had clinical benefit.
Conclusion
Cell therapywith EBV-targeted autologous CTLs is safe, induces LMP-2-specific immunologic
responses, and is associated with objective responses and control of disease progression in
patients with stage IV NPC resistant to conventional treatments.
J Clin Oncol 23:8942-8949.  2005 by American Society of Clinical Oncology
INTRODUCTION
Nasopharyngeal carcinoma (NPC) occurs
worldwide and is the third most common
malignancy in southern China, where the
incidence is as high as 50 per 100,000 peo-
ple.1 While early stage NPC is curable with
radiotherapy and chemotherapy in more
than 80% of cases, the prognosis of patients
with either metastatic/locally advanced at
onset or recurrent disease remains poor.1,2
Second-line therapies can offer only a lim-
ited percentage of durable responses2 with
relevant toxicity in patients who, in most
cases, suffer frompermanent sequelae of pre-
vious radiotherapy, chemotherapy, or sur-
gery. Hence, alternative therapies capable
of improving disease-free survival and asso-
ciated with reduced toxicity are warranted.
Epstein-Barr virus (EBV) is present in
virtually all poorly differentiated and undif-
ferentiated nonkeratinizing NPCs regardless
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of geographic origin.3 Different from EBV-related post-
transplant lymphoproliferative disease (PTLD), NPC ex-
presses a restricted set of viral antigens, namely latent
membrane protein (LMP) 1 and 2, and EBNA1,4 immuno-
gens that are weak albeit capable of inducing a T-lymphocyte
response.5-7 Because it has been shown that NPC cells
are capable of immunologic processing for cytotoxic
T-lymphocyte (CTL) recognition,8,9 and on the basis of
the success of adoptive EBV-targeted CTL therapy for
EBV-related PTLD,10 the use of anti-EBV immunotherapy
strategies has been receiving increasing attention as a pos-
sible additional treatment to improve prognosis of ad-
vanced NPC.11-14 Studies of immune responses in NPC
patients have demonstrated a generalized immunosup-
pression with decrease of cell-mediated cytolysis.15,16 In
addition, it has been shown that EBV-targeted T-lymphocyte
immunity is signiﬁcantly reduced in NPC patients com-
pared with healthy EBV carriers,12,17 although a measur-
able frequency of LMP2-speciﬁc CTL precursors (CTLp)
has been detected often.18
Immunization with dendritic cells pulsed with EBV-
peptides was reported to enhance speciﬁc T-lymphocyte
immunity and induce partial tumor reduction in patients
with advanced NPC.19 However, so far, there is limited ev-
idence that EBV-targeted CTLs expanded from blood of
NPC patients are capable of homing at the tumor site and
of exerting efﬁcient tumor killing in vivo. Our group has
recently reported the case of a patient with radiotherapy-
and chemotherapy-resistant metastatic NPC treated with
EBV-targeted CTLs reactivated from lymphocytes of an
human leukocyte antigen (HLA) –matched related donor.
In this case, CTLs exhibited in vitro cytotoxicity against
autologous NPC tumor cells and, once administered in-
travenously, induced temporary stabilization of disease,
along with enhancement of patient EBV-LMP2-speciﬁc
T-lymphocyte response.14 In a pilot study in China, the
adoptive transfer of autologous EBV-targeted CTLs in-
duced antiviral responses but no clinical responses in four
NPC patients.12 Very recently, in a series of less advanced
NPC patients, including patients treated in the adjuvant
setting, autologous EBV-targeted CTL infusions proved
safe and effective in promoting clinical tumor response.20
In the current study, we report the results of a trial of
immunotherapy with autologous EBV-targeted CTLs in
patients with stage IV radiotherapy- and chemotherapy-
resistant EBV-related NPC, demonstrating an enhance-
ment of EBV-speciﬁc immune responses together with
clinical responses.
PATIENT AND METHODS
Patients
Eligible patients were younger than 70 years with histolog-
ically conﬁrmed stage IV EBV-LMP1 and/or EBV-encoded,
RNA-positive NPC that was radiographically documented to
be in progression despite prior conventional therapies and was
not amenable to complete surgical resection or further systemic
or local conventional treatments. Patients were required to have
normal organ function and were excluded in case of active brain
metastases, or if they had received any treatment for their disease
within 30 days before enrollment, or were undergoing immuno-
suppressive therapy. Ten consecutive patients were enrolled on
the study. Patient characteristics are reported in Table 1.
Throughout the study period, the patients received EBV-speciﬁc
Table 1. Main Clinical Characteristics and Clinical Outcome of Patients With NPC in Progression After Conventional Therapies and Treated
With EBV-Targeted CTL Therapy
Patient
No. UPN
Age
(year) Sex
Stage at
Diagnosis
Site(s) of Tumor
Involvement at Time
of Cell Therapy Prior Therapies*
ECOG
PS
CTL
Infusions Adverse Effects
Response to
Therapy
(duration)
1 10002348 40 Male II (T2N1M0) Bone, bone marrow,
liver
RT,  2 lines of CT 2 2 None PD
2 30208742 46 Male III (T3N2M0) Lymph nodes RT, 2 lines of CT,
surgery
0 10 Inflammatory reaction
in the disease site
PR (3 months)
3 30233207 22 Male III (T2N2M0) Lymph nodes, soft
tissues, bone
RT,  2 lines of CT,
surgery of bone
metastasis
0 23 None SD (15 months)
4 30345153 17 Male Unknown Parapharyngeal tissue,
lymph nodes
RT,  2 lines of CT
surgery
0 14 None SD (4 months)
5 10043598 70 Male IVA (T4N1M0) Lung, skull base RT, 2 lines of CT, surgery 1 5 None PD
6 30110679 63 Male III (T1N2M0) Nasopharinx, skull
base
RT, 2 lines of CT,
surgery
2 2 Adverse effects due
to IL-2 therapy
PD
7 30486646 60 Male IIB (T1N1M0) Liver, lymph nodes RT,  2 lines of CT 2 11 Adverse effects due
to IL-2 therapy
PR (5 months)
8 30287851 48 Male IVC (T2N2M1) Primary tumor, liver RT,  2 lines of CT 0 6 None PD
9 30376608 54 Male IVB (T4N3M0) Nasopharinx,
lymph nodes, skull
base
RT, 2 lines of CT 2 12 None SD (4 months)
10 30545247 50 Male III (T3N2M0) Lymph nodes. liver RT,  2 lines of CT 0 17 Single episode of
inflammatory reaction
in the disease site
SD (8 months)
Abbreviations: EBV, Epstein-Barr virus; UPN, unique patient number; ECOG PS, Eastern Cooperative Oncology Group performance status; UPN, unique
patient number; CTL, cytotoxic T lymphocytes; CT, chemotherapy; RT, radiotherapy; SD, stable disease; PR, partial response, PD, progressive disease.
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CTLs as single-agent treatment. Approval for this study was ob-
tained from the competent Institutional Review Boards at IRCCS
Policlinico S. Matteo for the ex-vivo generation of EBV-targeted
CTLs and at Ospedale Niguarda Ca’ Granda for in-vivo treat-
ment of NPC patients. Patients gave written informed consent
before enrolment.
Generation and Characterization of
EBV-Speciﬁc CTLs
Harvest and isolation of peripheral blood mononuclear
cells. Because peripheral blood lymphocyte counts were low
in all patients, peripheral blood mononuclear cells (PBMCs)
and autologous plasma were collected through a single leukaphe-
resis. Leukapheretic procedure was aimed at obtaining a number
of PBMCs ranging from 1 to 2 109, considering, from previous
experience, a minimal cellular expansion of three-fold total cel-
lular yield reached the desired target number in all cases. PBMCs
were isolated by Ficoll-Hypaque density gradient centrifugation,
resuspended in X-VIVO 20 medium (BioWhittaker, Walkersville,
MD) with 2% autologous plasma (X-VIVO-AHS), and either
used fresh or cryopreserved.
Production of autologous EBV-transformed B-lymphoblastoid
cell line. PBMCs were incubated with EBV-containing su-
pernatant from the B95-8 cell line (American Type Culture Col-
lection, Rockville, MD) in the presence of 800 ng/mL of
cyslosporine-A (Sandoz Pharmaceuticals, Basel, Switzerland).
Cells were continuously cultured for 3 to 4 weeks, following a
protocol previously described.21
Preparation of autologous EBV-speciﬁc CTL lines. EBV-
speciﬁc CTLs were reactivated and expanded in vitro according
to a method previously reported, following good laboratory
practice (GLP) standard procedures.22 Before cryopreservation,
T cells were examined for immunophenotype, sterility, and
EBV speciﬁcity in a standard 51Cr-release assay against a panel
of targets including autologous B-lymphoblastoid cell line
(LCL), autologous phytohemagglutinin (PHA) blasts pulsed
with 2 g/mL of a peptide mix containing 15-mer peptides
spanning the EBV LMP2 protein (Jerini, Berlin, Germany),
and autologous tumor cells. Tumor cells were obtained from a
baseline tumor biopsy, according to a previously published
method.14 Early-passage neoplastic cells were used to minimize
the possibility of loosing primary characteristics as a consequence
of extensive in vitro reculturing.
Flow cytometry. Monoclonal antibodies used to characterize
cultured cells were CD3 (anti-Leu-4) ﬂourescein isothiocyanate
(FITC), anti–HLA-DR phycoerythrin (PE), CD8 (anti-Leu-2a)
FITC and PE, CD56 (anti-Leu-19) PE, anti-TRC  FITC, CD4
(anti-Leu-3a) PE, CD19 (anti-Leu-12) FITC, CD20 (anti-Leu-
16) PE, CD45 (anti-HLe-1) FITC (Becton Becton Dickinson,
Mountain View, CA). Appropriate isotype-matched controls
were included. Cytoﬂuorimetric analysis was performed by
means of direct immunoﬂuorescence on a FACScan ﬂow cytom-
eter (Becton Becton Dickinson).
EBV-Speciﬁc CTL Infusion Schedule and
Patient Evaluation
Cryopreserved CTLs were thawed rapidly and administered
intravenously. Patients were monitored for vital signs before and
immediately after each infusion. Autologous CTLs were infused
at weekly intervals for the ﬁrst four administrations and subse-
quently every 2 to 4 weeks. For the ﬁrst ﬁve patients, CTL infu-
sion schedule included a ﬁrst dose of 2  107 CTL/m2 of body
surface, followed by subsequent doses of 4  107 CTL/m2. This
infusion scheme was derived from that employed in the treat-
ment of EBV-associated lymphoproliferative disease after trans-
plantation.10,21 In the last ﬁve patients (patients 6 to 10), the
schedule was modiﬁed to deliver a higher number of CTLs,
and the patients received four escalating doses of EBV CTL
(2  107, 4 107, 6  107, and 8  107 CTL/m2) every 2 weeks,
followed by infusions of 6  107 CTL/m2 every 2 to 4 weeks,
accompanied by administration of low-dose recombinant
interleukin-2 (IL-2; Chiron, Milan Italy; 1  106 U subcutane-
ously qd) with the aim of prolonging T-lymphocyte life span.
We planned to deliver the ﬁrst ﬁve to six doses of CTLs until
disease evaluation, and continue with CTL infusions in case of
evidence of clinical beneﬁt. In all patients, cell therapy was dis-
continued upon evidence of disease progression.
Disease evaluation was performed according to the criteria
proposed by the Response Evaluation Criteria In Solid Tumors
(RECIST) Committee22 after 1 month and every 2 months there-
after. To evaluate the effects of CTL administration on the fre-
quency of IFN- secreting lymphocytes and on EBV-directed
cytotoxic activity, peripheral blood samples were collected at
baseline, and at different times after CTL infusions. EBV DNA
levels were monitored by PCR21 on plasma samples.
Enzyme-Linked Immunospot Assay
For enzyme-linked immunospot (ELISPOT) assay, 96-well
multiscreen ﬁlter plates (MAIPS 4510, Millipore, Bedford, MA)
were coated with 100 L of primary antibody (IFN-, Mabtech,
Nacka, Sweden) at 2.5 g/mL, and incubated overnight at 4°C.
Peripheral blood mononuclear cells (PBMCs) were thawed and
cultured overnight in RPMI medium with 10% fetal calf serum
before use in the assay, and were then seeded in the presence of
EBV-LCL or 2 g/mL of the EBV LMP-2 peptide mix. After in-
cubation for 24 hours at 37°C, 100 L of biotinylated secondary
antibody (Mabtech, 0.5 g/mL) was added, and plates were then
processed according to standard procedure.23 IFN-–producing
spots were counted using a Elispot reader (Bioline, Torino, Italy).
The number of spots per well was calculated after subtraction of
assay background, quantitated as average of 24 wells containing
only sterile complete medium, and speciﬁc backgrounds, quan-
titated as the sum of cytokine spots associated with responders
alone, EBV-LCL alone, responders plated with dimethyl sulfoxide
solvent control, as appropriate.
LMP2-Speciﬁc Cytotoxicity Assay
Speciﬁc cytotoxic activity before and after CTL infusion was
assessed according to a method previously described.13 In brief,
cryopreserved PBMCs were thawed and incubated for 24 hours
with 10 U/mL rIL-2 and 2 g/mL of the EBV LMP2 peptide mix,
after depletion of CD16 and CD56 cell populations. As targets,
3-day PHA blasts were pulsed with 2 g/mL of the EBV LMP2
peptide mix or with control peptide.
RESULTS
Biologic Characterization of EBV-Targeted
Autologous CTL Lines Utilized for
Cell Therapy
EBV-transformed autologous B-LCL and autologous
EBV–speciﬁc CTL lines were successfully generated ex
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vivo from all 10 patients. Growth kinetics of the T-cell
lines from our cohort of NPC patients with disease pro-
gression corresponded to a median ﬁve-fold cell expansion
at 4 weeks (range, 2 to17 weeks), thus comparable to what
was observed previously for healthy donors.24
Phenotypic ﬂow cytometry analysis indicated that the
CTL lines generated from PBMCs of NPC patients were
heterogeneous with respect to the percentages of CD3/
CD8, CD3/CD4 and CD4/CD8 ratio (Table 2). In de-
tail, CD8 cells ranged from 30% to 89% (median, 67%),
CD4 lymphocytes ranged from 8% to 68% (median
29%), and CD3/HLA-DR population was between
54% and 96% (median 87%). Moreover, the CTL lines
contained a median of 20% cells that were CD3/
CD8/CD56 and 5% cells with natural killer phenotype
(CD56/CD3). The proportion of TCR cells was
very low in all patients.
To test EBV speciﬁcity of CTLs, we measured cytotox-
icity against autologous LCLs or HLA-mismatched LCLs,
as well as against allogeneic PHA blasts. CTLs from NPC
patients contained HLA-restricted components, since
lysis of autologous LCLs was always higher than that of
HLA-mismatched LCLs (Table 2). No lysis against alloge-
neic PHA blasts was observed. Activity of EBV CTL
lines against LMP2 protein was present in ﬁve of the 10
patients (Fig 1).
The presence of in vitro activity of CTLs against
autologous NPC cells, possibly predictive of an in vivo
antitumor effect, was also assessed whenever autologous
tumor cell lines were available. The level of cytotoxicity
against patient tumor cells, tested in four patients, ranged
between 7% and 20% (median, 15%) at an effector-to-
target ratio of 10:1 (Fig 1).
Clinical Effects of Autologous EBV-Targeted
CTL Therapy
Patients enrolled in this trial received a median of 10
CTL administrations (range, 2 to 23). Hospital admission
was not required. During CTL administration, no acute
adverse effects occurred. One to 2 days after each CTL
administration, patient 2 had grade 2 inﬂammation at
the tumor site (suvraclavear and laterocervical nodes) re-
quiring antiinﬂammatory medication, including steroids,
and causing treatment delays. Patient 10 had an inﬂam-
matory reaction at the site of neck lymph node involve-
ment at the time of the 12th CTL administration. No
other late adverse effect ascribable to CTL therapy was
observed in the remaining patients. Two patients receiv-
ing IL-2 experienced mild adverse effects related to this
drug (ie, malaise, fever, chills), that in one case led to
IL-2 discontinuation because of poor compliance. In all
patients, cell therapy was discontinued upon evidence
of disease progression.
Clinical response to CTL therapy is summarized in
Table 1. Four patients achieved stable disease (SD) lasting
a median of 6 months (range, 4 to 15 months). Patient 10
persists in SD at the time of this writing. Patients 2 and 7
achieved partial response (PR) 3 and 4 months after the
ﬁrst CTL infusion, respectively. Patient 2, notwithstanding
the achievement of a PR, refused to continue CTL therapy,
and was lost to follow-up. Patient 7 presented with mas-
sive liver metastases involving more than 75% of the or-
gan. Within 24 hours from the ﬁrst CTL infusion, an
increase in the levels of plasma EBV DNA levels was ob-
served, from a baseline value of 1,310 copies/L to
2,136 copies/L, likely due to lysis of tumor cells bearing
the viral genome. Three weeks after the fourth infusion,
EBV DNA levels were 940 copies/L. During the ﬁrst
month of CTL therapy a reduction of the levels of EBV
DNA, liver necrosis and cholestasis enzymes was observed,
together with an improvement of the performance status
from 2 to 0. Tumor regression was conﬁrmed by com-
puted tomography (CT) scan and CT-aided positron
emission tomography (PET) imaging (Fig 2). Eventually,
tumor progression occurred after 5 months and the pa-
tient died as a result of liver failure.
Table 2. Characteristics of EBV-Targeted CTL Lines Generated From Patients With NPC Evaluated in This Study
Patient
No. UPN
CD3/CD4
Cells (%)
CD3/CD8
Cells (%)
CD3/DR
Cells (%)
TCR
Cells (%)
CD3/56
Cells (%)
CD56/CD3-
Cells (%)
Auto LCL
(% lysis)
Allo LCL
(% lysis)
Allo PHA
(% lysis)
1 10002348 28 70 87 4 8 2 73 13 3
2 30208742 41 65 87 7 16 0 33 4 1
3 30233207 47 30 54 3 10 30 49 5 5
4 30345153 34 52 70 5 21 26 38 20 0
5 10043598 29 70 91 5 20 10 37 10 0
6 30110679 9 63 84 1 20 32 39 28 1
7 30486646 68 32 88 2 6 7 61 19 2
8 30287851 8 89 92 4 30 3 64 17 2
9 30376608 10 87 95 2 20 3 32 9 1
10 30545247 30 69 96 10 40 2 96 10 0
Median 29 67 87 4 20 5 44 11 1
Range 8-68 30-89 54-96 1-10 6-40 0-32 32-96 4-28 0-5
NOTE. The cytotoxicity results are reported for an effector to target ratio of 10:1.
Abbreviations: EBV, Epstein-Barr virus; CTL, cytotoxic T lymphocyte; NPC, nasopharyngeal carcinoma; UPN, unique patient number; LCL, B-lymphoblastoid
cell line; PHA, phytohemagglutinin.
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Immunologic Effects of EBV-Targeted
Autologous CTL Therapy
To determine the effect of CTL infusions on speciﬁc
immunity, frequency of IFN-–producing cells and spe-
ciﬁc cytotoxic capacity were evaluated on samples ob-
tained at different times after T-cell transfer. All patients
had detectable, albeit very low in comparison to healthy
EBV-seropositive donors,24 levels of EBV-LCL–speciﬁc
IFN-–producing cells before CTL therapy (Fig 3B).
Upon T-cell transfer, the frequency of LCL-speciﬁc T cells
increased (Fig 3B).
Before EBV-speciﬁc CTL therapy, levels of LMP2-
speciﬁc IFN-–secreting cells were undetectable or very
low in all patients ( 2/105 PBMCs; Fig 3A). After two to
four infusions (ie, 2 to 4 weeks after the ﬁrst CTL dose),
four of the 10 patients (patients 1, 3, 7, and 10) showed
a measurable response, that initially increased with the
number of CTL infusions, the mean peak frequency ob-
served being 34/105 PBMCs (Fig 3A). Patient 2, who
had a clinical response to treatment, and patients 4 and
9, who showed tumor stabilization, did not reveal detect-
able levels of LMP2-speciﬁc T cells in their peripheral
blood. We then proceeded to evaluate whether the
LMP2-speciﬁc IFN-–producing cells present in the
PBMC of the patients after CTL therapy were also en-
dowed with cytotoxic capacity. In line with the IFN-
production data, PBMC collected postinfusion from pa-
tients 3 and 7 displayed measurable lytic activity against
LMP2-bearing targets compared with cells harvested at
baseline (cytotoxicity at a 10:1 effector-to-target ratio:
8  1 and 10  2, respectively), whereas lymphocytes
%
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Fig 1. Functional characteristics of the infused Epstein-Barr virus–targeted
cytotoxic T-lymphocyte (CTL) lines. Cytotoxicity of CTL reactivated from the
10 patients, in response to autologous EBV–B-lymphoblastoid cell lines (gold
bars), autologous EBV LMP-2 protein peptide mix-pulsed PHA blasts (brown
bars), and autologous tumor cells (blue bars) is reported. Results represent
mean cytotoxicity at a 10:1 effector to target (E:T) ratio standard deviation.
C
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B
Fig 2. Objective response to Epstein-
Barr virus (EBV) –targeted cytotoxic
T-lymphocyte (CTL) therapy in patient
7. (A and B) Computed tomography–
aided positron emission tomography
imaging before T-cell therapy shows
massive liver involvement. (C and D)
After 3 months of EBV-targeted CTL
therapy, reduction of size and isotope
uptake of NPC lesions was detected.
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obtained from patients 2 and 5 did not show lysis of
LMP2-bearing targets.
In all patients, the levels of both EBV-LCL-speciﬁc and
LMP2-speciﬁc cells declined over time (data not shown).
DISCUSSION
In the present study, we demonstrate that clinical and
immunologic responses can be obtained in patients with
radiotherapy- and chemotherapy-resistant stage IV EBV-
related NPC by administration of EBV-targeted autolo-
gous polyclonal CTL therapy. In particular, we document
that despite multiple lines of previous immunosuppressive
treatments, it is feasible to reactivate and expand ex vivo
CTLs that possess normal cytotoxic activity against autol-
ogous EBV-infected B-cell lines. Moreover, EBV-targeted
CTL administered intravenously appear safe also in heavily
pretreated patients with bulky disease. More importantly,
even though the patients enrolled had progressive, stage IV
NPC after failure of conventional treatments, tumor con-
trol related to cell therapy did occur.
Clinical responses consisting of objective partial re-
mission occurred in two patients, whereas four patients
maintained stable disease for an overall 60% control of
disease progression. This ﬁgure represents a remarkable
clinical result if one considers that patients enrolled in
this study were indeed eligible for supportive care only,
and had an extensive tumor burden. In addition, CTL
therapy was well tolerated, with mild adverse effects in
a minority of patients.
For the two patients showing a reduction of tumor
burden, it was not possible to obtain a postinfusion bi-
opsy. Therefore, we could not perform a T-cell receptor
repertoire analysis by CDR3 spectratyping and sequencing,
which would have provided information on a possible
homing of infused CTL at the tumor site through charac-
terization of T-cell clonotypes present in the lesion after
T-cell infusion, and a comparison to clonotypes included
in the transferred CTL line. However, in these patients
showing objective responses, autologous CTL therapy
was associated with either symptoms suggestive of CTL
trafﬁcking at the tumor site (patient 2) or an increase of
EBV-DNA plasma levels, reminiscent of tumor lysis (pa-
tient 7). These latter observations provide further evidence
suggesting that infused CTLs were directly responsible for
tumor reduction.
Immunologic responses to CTL therapy occurred in
all patients, with four of 10 patients showing a boost of
LMP2-speciﬁc cell frequency detected in peripheral blood.
These LMP2-speciﬁc cells were functional, since they pro-
duced IFN- and displayed some lytic activity against
LMP2-bearing autologous NPC targets. It is noteworthy
that, in three of the four patients, the development of
an LMP2-speciﬁc response coincided with a clinical ben-
eﬁt. For the remaining patients, in whom a clinical re-
sponse was observed in the absence of a detectable
enhancement of LMP2-speciﬁc immunity in the periph-
ery, we hypothesize that either CTLs, homing at the
tumor site, were not recirculating in the peripheral blood,
or that the immune response was directed towards LMP1
or EBNA 1 antigens,20 which we could not test, rather
than LMP2.
We delivered CTLs weekly for the ﬁrst month, and
subsequently at 2- to 4-week intervals in the attempt to
augment efﬁcacy of T-cell therapy based on the knowledge
that autologous CD8 T cell clones infused in patients
with melanoma persisted for a median of 7 days after
transfer.25 Moreover, since the administration of systemic
IL-2 appears to prolong in vivo persistence of infused
lymphocytes,25 we further implemented our treatment
protocol by using low-dose IL-2 in ﬁve patients. Notwith-
standing the increased anti-LMP2 immunity occurring in
some patients, and the attempts to prolong CTL survival
in vivo, the clinical response in our patients was often
transient. This may be related to the large tumor burden
and advanced stage of disease of the patients enrolled in
this study, which might have favored treatment-induced
selection for antigen loss variants, associated to a generally
low activity of CTL lines against autologous tumor cells.
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Fig 3. Immunologic effect of Epstein-Barr virus (EBV)–targeted cytotoxic T-lymphocyte (CTL) therapy on patient EBV-specific interferon- (IFN-) production. IFN-
–secreting lymphocytesweremeasured in peripheral bloodmononuclear cells (PBMCs) obtained from the 10 patients before (green bars), 4weeks (red bars), and
8 weeks (orange bars) after CTL therapy, in response to (A) EBV–latent membrane protein 2 protein peptide mix and (B) EBV–B-lymphoblastoid cell lines (LCL).
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In our study, we employed CTLs stimulated with
EBV-LCL. The lines thus obtained potentially include spe-
ciﬁcities towards any latent antigen, albeit with a preferen-
tial selection of cells directed against immunodominant
proteins, such as EBNA3. Since NPC tumor cells express
a restricted pattern of EBV antigens, antitumor responses
could be further enhanced by strategies aimed at increas-
ing the number of LMP2 and/or LMP1-speciﬁc T cells in
the infusion product. In particular, enrichment of sub-
dominant antigen speciﬁcities through either stimulation
with dendritic cells expressing LMP2 and/or LMP1 and/or
EBNA1,26,27 or expansion of LCL-stimulated CTL after
vaccination of patients with LMP2 peptide–pulsed den-
dritic cells13 or LMP1 polyepitope adenovirus vaccine,28
could be obtained. The number of cells in each dose
that we administered in this phase I trial was relatively
small, if compared to the magnitude of infusions reported
in other studies of T-cell therapy for cancer.29 Thus, an ad-
ditional improvement to our current protocol will be the
administration of higher CTL doses. In addition, the po-
tential for CTL expansion in vivo may be augmented in the
condition of profound lymphopenia, such as following the
administration of lymphoablative chemotherapy.29
Overall, our phase I-II study document that the intra-
venous administration of autologous EBV-speciﬁc CTLs is
safe, augments EBV-speciﬁc immune responses, and pro-
duces clinical responses in patients with stage IV NPC.
However, as also demonstrated for the treatment of
EBV-related PTLD,30 CTLs used as monotherapy may
have the same limitations described for chemotherapy,
namely selection of malignant clones with poor expression
of EBV antigens, and thus refractory to CTL killing. Based
on original evidences presented and discussed in the pre-
ceding sections, we intend to pursue further studies of
cell therapy with EBV-targeted CTLs either earlier in the
course of NPC disease or in association with other con-
ventional therapeutic modalities,30,31 with the aim of reduc-
ing the risk of tumor selection and thus ameliorating the
clinical outcome.
- - -
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